Track topics on Twitter Track topics that are important to you
Oncohist™ exhibits the same properties as the body's own histone H1.3 molecules and has consequently low immunogenicity and antigenicity. Extensive data have shown that Oncohist molecules have the ability to destabilize selectively the tumor cell membrane which results in cell death. The selective attack of the membrane of tumor cells is due to the ability of Oncohist™ molecules to recognize the difference in membrane structure between tumor cells and their healthy counterparts. We believe that Oncohist™ has superior advantages over conventional cancer therapeutics, including high selectivity, low inherent toxicity, lack of induction of resistance and low immunogenicity.
A pilot clinical study (phase I/II) with Acute Myeloid Leukemia (AML) patients has been performed at the Saarland University Hospital at Homburg/Saar, Germany. The data showed that Oncohist™ is safe and well tolerated by patients while the first encouraging signs of clinical effect included three partial remissions, increase of thrombocytes and normalization of leukocytes as well as stabilization for several months in two patients.
Oncohist™ has been granted orphan drug status for Acute Myeloid Leukemia (AML) by both the FDA and EMA and additional orphan drug status for Acute Lymphocytic Leukemia (ALL) in Europe by the EMA.
Oncohist is a registered trademark of Xenetic Biosciences plc
SummaryXenetic Biosciences Inc Xenetic Biosciences, formerly General Sales Leasing Inc is a clinicalstage biopharmaceutical company that discovers and develops nextgeneration biologic drugs and novel...
SummaryXenetic Biosciences Inc Xenetic, formerly General Sales Leasing, Inc., is a clinicalstage biopharmaceutical company, which focuses on the discovery and development of biologic drugs and innova...
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...